Back to Journals » Drug Design, Development and Therapy » Volume 7
Profile of tivozanib and its potential for the treatment of advanced renal cell carcinoma
Authors Cowey CL
Received 3 December 2012
Accepted for publication 6 February 2013
Published 21 June 2013 Volume 2013:7 Pages 519—527
DOI https://doi.org/10.2147/DDDT.S31442
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
C Lance Cowey
Baylor-Sammons Cancer Center, Texas Oncology, PA, US Oncology Research, Dallas, TX, USA
Abstract: Tivozanib is a novel vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGF TKI). Among other VEGF TKIs, tivozanib stands apart due to its selective kinase inhibitory properties as well as its high potency for inhibiting VEGF receptors 1 and 2. Tivozanib has been evaluated in several clinical trials including a Phase I and Phase II trial demonstrating safety and efficacy for patients with advanced clear cell renal cell carcinoma (RCC). A pivotal randomized Phase III trial comparing the front-line use of tivozanib to sorafenib in patients with metastatic clear cell RCC has been reported. The clinical development of tivozanib and results of these important studies will be reviewed. Also, the potential placement of tivozanib among currently US Food and Drug Administration approved agents for advanced RCC will be discussed.
Keywords: tivozanib, AV-951, metastatic renal cell carcinoma, RCC, VEGF inhibitor, targeted therapy, angiogenesis inhibitor
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.